Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Omeprazole and Sodium Bicarbonate for oral suspension and Omeprazole and Sodium Bicarbonate capsules are indicated in adults for the : short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. short-term treatment (4 to 8 weeks) of active benign gastric ulcer. FDA label
Also known as Omeprazole IV
Omeprazole · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Omeprazole | DRUG | - |
Inclusion Criteria: * Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy. Written informed consent, ability to comply with study instructions Excl...
Top 1 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | PHAT | 2 | PHASE3 | Vonoprazan |
Omeprazole is used to treat gastroesophageal reflux disease (GERD) and non-erosive reflux disease. It is a small molecule developed by AstraZeneca PLC (ticker: AZN) and has been studied in Phase 3 clinical trials for these gastrointestinal conditions.
Omeprazole targets ATP4A and ATP4B, which are subunits of the gastric proton pump. It acts as an inhibitor of this target, reducing gastric acid secretion. This mechanism underlies its use in acid-related gastrointestinal disorders such as GERD and non-erosive reflux disease.
Omeprazole is developed by AstraZeneca PLC, which trades under the ticker AZN. The company has conducted Phase 3 clinical trials of the drug for gastrointestinal indications including GERD and non-erosive reflux disease.
Omeprazole has been studied in Phase 3 clinical trials. The development program includes completed trials for GERD and non-erosive reflux disease. It is an investigational product in these settings and has not been approved by the FDA for these indications based on the available information.
Omeprazole has been evaluated in Phase 3 trials including NCT00259077, which studied four-week treatment of non-erosive reflux disease in a Japanese population; NCT00259051, a pharmacodynamic study in the same population; and NCT00256737, which compared omeprazole treatment versus surgery in patients with GERD.